April 11, 2019
Authored and Edited by Matthew J. Hlinka; M. Andrew Holtman, Ph.D.
On April 4, 2019, FDA issued final guidance on FDA’s application of the statutory factors in determining when a risk evaluation and mitigation strategy (REMS) is necessary. This guidance clarifies how FDA determines whether a REMS is necessary to ensure that a drug is used in a way where its benefits outweigh its risks.
A drug can only receive FDA approval if it is shown that the drug is safe and effective when used according to its label. However, a determination that a drug is safe does not necessarily mean that the drug is entirely free from harmful or undesirable effects. Instead, it means that the likelihood of a positive treatment outcome outweighs the probability and magnitude of any adverse effects. A REMS is one tool that FDA can develop and utilize to preserve a drug’s benefits while reducing its risks to an acceptable level. For example, a REMS may require health care providers who prescribe the drug to undergo specialized training, or mandate that the drug only be dispensed to patients in certain health care settings, such as hospitals, where the patient can be closely monitored. If FDA determines that a drug’s risks would exceed its benefits even if a REMS is required, FDA will not approve the drug.
Section 505-1(a)(1) of the FDCA requires FDA to consider six factors when determining whether a REMS should be required:
No single factor is determinative, and the relative weight of each factor is a case-specific inquiry. In addition to the six factors listed above, FDA will also consider the potential burdens that a REMS may impose on patients and health care providers, and whether a REMS can be designed that adequately minimizes those burdens.
Readers are encouraged to read the final guidance, also available on FDA’s website.
Food and Drug Administration (FDA), FDA Guidance, drugs, Federal Food Drug and Cosmetic Act (FDCA), new drug application (NDA)
Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
10th Annual Georgia Asian Pacific American Bar Association Gala
May 29, 2024
Atlanta
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.